Antiviral agents for the treatment of COVID-19: Progress and challenges

The COVID-19 pandemic has seen clinical development and use of antiviral therapies at an unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in COVID-19 patients, especially when administered early after diagnosis. Here, we discuss the successes and challenges of COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Manmeet, de Wit, Emmie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831133/
https://www.ncbi.nlm.nih.gov/pubmed/35474740
http://dx.doi.org/10.1016/j.xcrm.2022.100549
_version_ 1784648435019808768
author Singh, Manmeet
de Wit, Emmie
author_facet Singh, Manmeet
de Wit, Emmie
author_sort Singh, Manmeet
collection PubMed
description The COVID-19 pandemic has seen clinical development and use of antiviral therapies at an unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in COVID-19 patients, especially when administered early after diagnosis. Here, we discuss the successes and challenges of COVID-19 antiviral therapies and lessons for future pandemics.
format Online
Article
Text
id pubmed-8831133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88311332022-02-11 Antiviral agents for the treatment of COVID-19: Progress and challenges Singh, Manmeet de Wit, Emmie Cell Rep Med Commentary The COVID-19 pandemic has seen clinical development and use of antiviral therapies at an unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in COVID-19 patients, especially when administered early after diagnosis. Here, we discuss the successes and challenges of COVID-19 antiviral therapies and lessons for future pandemics. Elsevier 2022-02-11 /pmc/articles/PMC8831133/ /pubmed/35474740 http://dx.doi.org/10.1016/j.xcrm.2022.100549 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Commentary
Singh, Manmeet
de Wit, Emmie
Antiviral agents for the treatment of COVID-19: Progress and challenges
title Antiviral agents for the treatment of COVID-19: Progress and challenges
title_full Antiviral agents for the treatment of COVID-19: Progress and challenges
title_fullStr Antiviral agents for the treatment of COVID-19: Progress and challenges
title_full_unstemmed Antiviral agents for the treatment of COVID-19: Progress and challenges
title_short Antiviral agents for the treatment of COVID-19: Progress and challenges
title_sort antiviral agents for the treatment of covid-19: progress and challenges
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831133/
https://www.ncbi.nlm.nih.gov/pubmed/35474740
http://dx.doi.org/10.1016/j.xcrm.2022.100549
work_keys_str_mv AT singhmanmeet antiviralagentsforthetreatmentofcovid19progressandchallenges
AT dewitemmie antiviralagentsforthetreatmentofcovid19progressandchallenges

Ejemplares similares